These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 2942238)

  • 1. Immunomodulatory and therapeutic properties of bestatin in mice.
    Talmadge JE; Lenz BF; Pennington R; Long C; Phillips H; Schneider M; Tribble H
    Cancer Res; 1986 Sep; 46(9):4505-10. PubMed ID: 2942238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on the mechanisms of action of the immunomodulator Bestatin in various screening test systems.
    Schorlemmer HU; Bosslet K; Dickneite G; Lüben G; Sedlacek HH
    Behring Inst Mitt; 1984 May; (74):157-73. PubMed ID: 6383322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulatory properties of recombinant murine and human tumor necrosis factor.
    Talmadge JE; Phillips H; Schneider M; Rowe T; Pennington R; Bowersox O; Lenz B
    Cancer Res; 1988 Feb; 48(3):544-50. PubMed ID: 3257167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ability of the immunomodulating dipeptide bestatin to activate cytotoxic mononuclear phagocytes.
    Schorlemmer HU; Bosslet K; Sedlacek HH
    Cancer Res; 1983 Sep; 43(9):4148-53. PubMed ID: 6871856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease.
    Talmadge JE; Phillips H; Schindler J; Tribble H; Pennington R
    Cancer Res; 1987 Nov; 47(21):5725-32. PubMed ID: 3499218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acceleration of age-associated immune decline and mortality by early repeated administration of bestatin to C57BL/6 mice.
    Bruley-Rosset M; Payelle B; Rappaport H
    J Biol Response Mod; 1986 Apr; 5(2):176-90. PubMed ID: 3488372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Busulfan-induced suppression of natural killer cell activity.
    Bhoopalam N; Price KS; Norgello H; Fried W
    Exp Hematol; 1985 Dec; 13(11):1127-32. PubMed ID: 2933271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulation and antitumor effects of MVE-2 in mice.
    Talmadge JE; Maluish AE; Collins M; Schneider M; Herberman RB; Oldham RK; Wiltrout RH
    J Biol Response Mod; 1984 Dec; 3(6):634-52. PubMed ID: 6334720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The preclinical screening laboratory: evaluation of immunomodulatory and therapeutic properties of biological response modifiers.
    Talmadge JE; Herberman RB
    Cancer Treat Rep; 1986 Jan; 70(1):171-82. PubMed ID: 3510733
    [No Abstract]   [Full Text] [Related]  

  • 10. Aminopeptidase inhibitor ubenimex (bestatin) inhibits the growth of human choriocarcinoma in nude mice through its direct cytostatic activity.
    Inoi K; Goto S; Nomura S; Isobe K; Nawa A; Okamoto T; Tomoda Y
    Anticancer Res; 1995; 15(5B):2081-7. PubMed ID: 8572606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Experimental and clinical studies of bestatin as an immunomodulator].
    Miwa H; Oka T; Tsurumi T; Sakae Y; Orita K
    Gan To Kagaku Ryoho; 1982 Jul; 9(6):1019-24. PubMed ID: 7184437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
    Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
    Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do tuftsin and bestatin constitute a biopharmacological immunoregulatory system?
    Mathé G
    Cancer Detect Prev Suppl; 1987; 1():445-55. PubMed ID: 3319151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of bestatin on syngeneic tumors in mice.
    Abe F; Shibuya K; Uchida M; Takahashi K; Horinishi H; Matsuda A; Ishizuka M; Takeuchi T; Umezawa H
    Gan; 1984 Jan; 75(1):89-94. PubMed ID: 6586596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmentation of cellular immunity by kigamicin D.
    Masuda T; Ohba S; Kawada M; Iijima M; Inoue H; Osono M; Ikeda D; Kunimoto S
    J Antibiot (Tokyo); 2006 Apr; 59(4):215-9. PubMed ID: 16830888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Types of cellular antitumor cytotoxicity].
    Lomakin MS; Maĭskiĭ IN
    Vopr Onkol; 1988; 34(12):1422-32. PubMed ID: 2975420
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunological aspects of retinoids in humans. III. Effects of retinoic acid on the natural killing of tumor cells.
    Sidell N; Famatiga E; Shau H; Golub SH
    J Biol Response Mod; 1985 Jun; 4(3):240-50. PubMed ID: 3160830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulatory and immunotherapeutic properties of recombinant gamma-interferon and recombinant tumor necrosis factor in mice.
    Talmadge JE; Tribble HR; Pennington RW; Phillips H; Wiltrout RH
    Cancer Res; 1987 May; 47(10):2563-70. PubMed ID: 3105865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoregulation and immunostimulation of murine lymphocytes by recombinant human interleukin-2.
    Talmadge JE
    J Biol Response Mod; 1985 Feb; 4(1):18-34. PubMed ID: 3156969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulatory and therapeutic properties of FK-565 in mice.
    Talmadge JE; Lenz B; Schneider M; Phillips H; Long C
    Cancer Immunol Immunother; 1989; 28(2):93-100. PubMed ID: 2521814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.